Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment

pharmafile | March 30, 2016 | News story | Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III 

Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment of iron deficiency anaemia (IDA) in adults with non-dialysis dependent chronic kidney disease.

The oral, iron-based medicine met its primary endpoint and all pre-specified secondary endpoints with statistical significance. The primary endpoint – proportion of patients achieving an increase in haemoglobin of greater than, or equal to, 1.0 g/dL during the efficacy period – achieved sufficiently positive results, which were significantly higher than those receiving the placebo (52.1% compared to 19.1%)

It is estimated that 1.6 million people in the US suffer with stage 3-5 non-dialysis dependent chronic kidney disease and iron deficiency anaemia. If approved by the FDA, it will be the only such iron treatment in tablet form available to these patients.

John Neylan, chief medical officer at Keryx Biopharmaceuticals, comments: “These Phase III results demonstrate that ferric citrate can effectively raise haemoglobin levels in stage 3-5 non-dialysis dependent chronic kidney disease patients, with effects observed as early as two weeks post-treatment initiation.

“Based on these results, we plan to submit an sNDA to the FDA in the third quarter, seeking to expand the label for ferric citrate to include the treatment of iron deficiency anaemia in people with stage 3-5 NDD CKD. We believe that the ability to treat iron deficiency anaemia, managing haemoglobin and iron levels, could have an important effect on the way kidney specialists treat these patients.”

Early indications on the stock market showed that Keryx was trading heavily in pre-market trading, with this positive study having the potential to send their stock soaring, according to industry analysts.

Sean Murray

Related Content

Regeneron shares data for multiple myeloma treatment

Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as …

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical …

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Latest content